A familial case of Blau syndrome caused by a novel NOD2 genetic mutation

Article information

Abstract

Introduction

Blau syndrome (BS, MIM No. 186580) is a rare monogenic auto-inflammatory granulomatous disorder first described in 1985 by the pediatrician Edward Blau. It is an autosomal dominant chronic inflammatory syndrome with classical clinical triad of granulomatous dermatitis, symmetric arthritis and recurrent uveitis in young children1). Histology of affected tissues demonstrates epithelioid and multinucleated giant cells organized in typical granulomas.

BS and sarcoidosis show many similar features, such as noncaseating granuloma, skin rash and eye involvement. Early-onset sarcoidosis (EOS, MIM No. 609464) was previously considered to be a distinctive type of childhood sarcoidosis with a younger age of onset and a progressive course. BS and EOS are now considered to be the same disease, as both were later found to have mutations in NOD2 gene23).

The number of different NOD2 mutations associated with Blau has expanded greatly over the past decades. Currently, up to 30 different mutations in NOD2 have been reported in association with BS or other related diseases in the Human Genomic Mutation database45). There has been only one previous report of BS in Korean family, which showed a R334 W substitution, a common mutation in BS6).

Here, we describe a novel mutation in NOD2 gene shared by two siblings, and their clinical phenotypes.

Case reports

1. Case 1 (index case)

A 8-year-old girl presented with conjunctival injection which was later diagnosed as anterior uveitis that was treated with topical corticosteroid. She reported having generalized multiple small papules (Fig. 1A) since the age of 6 months. Her paternal aunt was recently diagnosed with sarcoidosis, and she was referred under the suspicion of sarcoidosis.

Fig. 1

(A) Erythematous papular skin lesions observed in the lower extremities of case 1. (B) Histopathology of skin biopsy (H&E, ×200) from case 1 showing noncaseating granulomatous inflammation (arrow).

On presentation, her blood pressure as measured in the upper extremities was 126/60 mmHg. The blood pressure in her lower extremities was lower, checking at 95/50 mmHg. Systolic bruit was audible over her left upper chest. Echocardiogram and computed tomography (CT) angiogram revealed stenosis of the thoracoabdominal aorta with diffuse luminal narrowing from the aortic isthmus to the suprarenal arteries (Fig. 2), suggestive of midaortic dysplastic syndrome. Laboratory tests including complete blood cell count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and thyroid function tests were all normal. A skin biopsy of her lower limbs showed noncaseating granulomatous inflammation (Fig. 1B). Case 1 was not treated with systemic immunosuppressive medications due to mild symptoms.

Fig. 2

3-Dimensional cardiac computed tomography image of case 1. Image shows stenosis at aortic isthmus (arrow).

2. Case 2

A 10-year-old brother of case 1 was referred for sarcoidosis work up. He had small erythematous papules of 1–2 mm in size in both arms (Fig. 3A). The skin lesion started to develop at the age of 6 months. He had subcutaneous nodules in the wrists and ankles. He complained of pain in multiple lower limb joints, especially while sitting down or squatting, indicating arthritic changes. He suffered from uveitis since very young age, which was treated by topical corticosteroids. His eye exam revealed multiple mild subepithelial opacities on both eyes (Fig. 4) along with focal posterior synechia. His blood pressure was normal and 1/6 systolic murmur was audible on auscultation, but echocardiogram was normal. CBC, ESR, CRP, and thyroid function tests were all normal. CT of chest and abdomen were normal. A skin biopsy of his lower limbs showed noncaseating granulomatous inflammation (Fig. 3B). Case 2 was also was not treated with systemic immunosuppressive medications due to mild symptoms.

Fig. 3

(A) Erythematous papular skin lesions observed in the lower extremities of case 2. (B) Histopathology of skin biopsy (H&E, ×200) from case 2 showing noncaseating granulomatous inflammation (arrow).

Fig. 4

Photograph of the anterior segment of the case 2 patient's eye. Irregular multiple subepithelial opacities are observed in the cornea (arrow).

3. Paternal family members

Their father (38 years) was also affected by uveitis but with minimal skin rashes. The paternal aunt (39 years) and her daughter (13 years) were diagnosed as sarcoidosis. They suffered from systemic erythematous skin rashes as well (Fig. 5).

Fig. 5

Pedigree analysis of the patients, BS, Blau syndrome.

Due to the siblings' early onset of symptoms and extensive family history of sarcoidosis like features, presence of BS was suspected.

Discussion

BS is a granulomatous autoinflammatory disease caused by mutation in the region encoding for the NOD2 gene with subsequent dysregulation of the inflammatory response and formation of non-caseating granulomas. Skin rash is the first symptom to appear in most cases, usually in the first year of life. In our case report, both siblings exhibited skin rash from 6months of age, which is consistent with BS. Polyarthritis is frequently observed between ages of 2–4 years, and uveitis develops in 60%–80% of the patients around the age of 48 months8). However in contrast to skin rashes, arthritis and uveitis sometimes can go undetected if symptoms are mild. Which is also true in our report, as case 1 presented with uveitis at the age of 8, and case 2 did not have evaluation regarding his joint discomfort until the age of 10 years.

NOD2 protein is a member of the NOD-like receptor family, primarily expressed in antigen-presenting cells, such as monocytes and macrophages. NOD2 has a tripartite structure with 2 N-terminal caspase recruitment domains, 1 centrally located NTPase triphosphatase domain (NACHT domain) and a C-terminal domain comprising multiple leucine rich repeat motifs, which bind muramyl dipeptide (MDP), a degradation product of the bacterial peptidoglycan. The MDP activates NOD2, which in turn activates nuclear factor kappa light chain enhancer of activated B cells (NF-κB), leading to inflammation and apoptosis2).

Here we report for the first time in Korea, a familial case of novel mutation of NOD2 causing BS. Genetic analysis of NOD2 from the 2 siblings revealed a novel SNV of an H480R mutation in the NACHT region. To date, 30 different mutations in NOD2 have been identified in patients with BS (n=14), early-onset sarcoidosis (n=7), pediatric granulomatous arthritis (n=5), granulomatous synovitis with uveitis (n=3) or Blau arteritis (n=1), mostly in the NACHT region459). Two of the mutations (R334Q and R334W) in the nucleotide-binding domain of the NOD2 gene are responsible for more than 50% of BS cases39), including a Korean case6). Because the activation of NOD2 involves oligomerization initiated by the NACHT-domain, mutations in this domain may decrease the threshold for spontaneous oligomerization of NOD210), and this gain-of-function mutation leads to the hyper-activation of NF-κB2).

Atypical cases of BS may display various additional features such as interstitial nephritis and cerebral infarction1112). Case 1 in our report exhibited vascular involvements, which is not a very common feature of BS. Previous reported cardiovascular manifestations of BS include Valsalva aneurysm as a form of auto-immune aortitis13), myocardial hypertrophy with the C495Y mutation14) and recurrent episodes of congestive heart failure with G481D mutation15). Both the C495Y mutation and the G481D mutation, causing cardiovascular changes showed a high level of MDP-independent NF-κB activation. It would be of interest to see if the novel mutation in H480R also leads to NF-κB activation.

Interestingly, case 1 showed vascular involvement, whereas case 2 prominently displayed joint involvement with early onset of uveitis. Family members sharing the same mutation often showed diverse clinical presentations in previous reported cases as well14). This may indicate that a specific monogenic genetic mutation is not enough to completely control phenotype, and other factors such as epigenetics are at work.

The family pedigree in our case strongly indicates that the BS mutation is inherited through the paternal side of the family. The father, paternal aunt and her daughter showing sarcoidosis like features are very likely to have mutation consistent with BS, although we were not able to confirm this with genetic analysis. As BS is inherited in autosomal dominant fashion, one can expect that one of the paternal grandparents to have been effected by BS but neither of the paternal grandparents showed significant symptoms. BS with very mild symptoms can go unnoticed, or one of the grandparents could have had germline mosaicism. The variability in clinical features in different family members adds difficulty in making early diagnosis of BS, as illustrated in our case. Although our sibling cases first demonstrated skin lesions at the age of 6 months, their diagnosis was delayed until the age of 8 and 10, respectively. Fortunately the siblings did not show significant visual disturbances or limitation of joint movements, but early detection of uveitis and arthritis is vital to prevent possible irreversible complications.

In conclusion, our report identifies a novel mutation in NOD2 gene that lead to a familiar case of BS. We emphasize that BS should always be considered in young patients presenting with systemic skin lesions and granulomatous inflammation, suggestive of early onset sarcoidosis or juvenile inflammatory arthritis. Early diagnosis through skin biopsy and genetic analysis can improve the quality of life and life expectancy of the patients. The clinical phenotype is highly variable even if same mutation is shared, and thorough multisystem work-up is warranted.

Article information Continued